Vall d'Hebron Hospital

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Endocrinologist and coordinator of the Obesity Unit at Vall d'Hebron Hospital.

Director of the Clinical and Molecular Genetics Department at the Vall d'Hebron Hospital in Barcelona

Oncologist at the Colon Cancer Unit of Vall d'Hebron Hospital.

Director of the Digestive System Research Unit at the Vall d'Hebron University Hospital in Barcelona and former president of the Spanish Society of Microbiota, Probiotics and Prebiotics (SEMiPyP)

Head of the Oncology Department of the Vall d'Hebron University Hospital of Barcelona and Director of the Vall d'Hebron Institute of Oncology

Specialist in obstetrics and maternal-fetal medicine at the Obstetrics Department of the Vall d'Hebron Hospital.

Director of the Clinical Neuroimmunology Laboratory at the Multiple Sclerosis Centre of Catalonia (Cemcat) and neurologist at the Vall d'Hebron University Hospital in Barcelona

Specialist in Pneumology at the Vall d'Hebron Hospital in Barcelona

Head of the Laboratory of Gene Therapy in Neurodegenerative Diseases of the VHIR-UAB Mixed Unit

Assistant doctor in the Paediatric Oncology and Haematology Department

Contents related to this centre

People taking heartburn medications suffer more migraines and severe headaches, says a study published in Neurology: Clinical Practice. According to the authors, these observations are consistent with other studies that link migraine and headaches to the use of proton pump inhibitors (such as omeprazole), and the new study adds a correlation with the use of other types of antacids. The analysis is based on data from more than 11,800 adults between 1999 and 2004 in the United States. 


Researchers have found specific antibodies in the blood of patients years before they showed symptoms of multiple sclerosis. This group of antibodies was present in 10% of the 250 people who later developed the disease, and were part of a sample of over 10 million US military personnel. The finding could have potential for early detection of multiple sclerosis, says the research team in a paper published in Nature Medicine


In the year 2023, Science magazine has chosen the development and discovery that GLP-1 medications, agonists of the glucagon-like peptide-1, can mitigate health issues associated with obesity as the most important scientific breakthrough. Similarly, Nature magazine has selected biochemist Svetlana Mojsov, a key figure in the discovery of GLP-1, as one of the top ten scientists of the year. 


A study has analysed the association between ambient temperature and hospital mortality from respiratory diseases in the provinces of Madrid and Barcelona between 2006 and 2019. Their results indicate that high summer temperatures were responsible for 16% and 22.1% of all fatal hospitalisations for respiratory diseases in Madrid and Barcelona, respectively. According to the team, led by ISGlobal, "unless effective adaptation measures are taken in hospitals, global warming could exacerbate mortality in patients admitted for respiratory diseases during the summer period". The research is published in the journal The Lancet Regional Health - Europe.

Bacteriophage virus

A team of scientists led by the Catholic University of America in Washington has designed new artificial vectors based on viruses to improve gene therapy processes. The main novelty is that they are constructed from viruses that infect bacteria. Among other advantages, this would make it possible to avoid the possible memory of our defences against them and have a greater capacity. According to the authors, who publish their results in the journal Nature Communications, these nanoparticles "have the potential to transform gene therapies and personalised medicine".


A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).


Obesity is a growing public health problem for the entire planet. According to the 2023 Obesity Atlas published this week by the World Obesity Federation, 51% of the world's population will be overweight or obese (more than 4 billion people) by 2035, up from 38% today. At a briefing organised by SMC Spain ahead of World Obesity Day on 4 March, two experts discussed the role that drugs can play in combating a disease whose roots are social and linked to inequality. 

Atrofia Muscular Espinal

Between 2018 and 2020, a pilot programme conducted neonatal genetic screening of children born in Australia for spinal muscular atrophy, allowing treatment to begin early. A study just published in The Lancet Child & Adolescent Health looks at their condition at two years of age and concludes that they had better movement ability, including the ability to walk, compared to children diagnosed once they develop symptoms. According to the authors, the findings justify further implementation of neonatal screening for the disease.

David Vetter

Bubble boy syndrome is a very serious condition caused by combined immunodeficiency. It is sometimes caused by certain mutations in the gene that codes for the Artemis protein. A phase I-II clinical trial has tested a gene therapy that adds a correct copy of the gene. The results are published in the journal NEJM.


A pioneering phase 1 clinical trial has tested a type of cancer immunotherapy. Researchers have modified patients' own T-lymphocyte receptors using the CRISPR tool to direct them against specific targets on their own tumours. The results are published in the journal Nature.